Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Medicines Agency (EMA) has accepted Shionogi's marketing authorisation application (MAA) for ospemifene.
Subscribe to our email newsletter
Ospemifene is developed as as vulvar and vaginal atrophy (VVA) therapy in post-menopausal women.
Shionogi CEO Takashi Takenoshita said the US Food and Drug Administration has approved ospemifene previous month.
"The acceptance of the MAA submission for ospemifene not only represents an important step forward in expanding the treatment options for women living in Europe with this condition, but it is also an important milestone for Shionogi as it continues to build its business in Europe," Takenoshita added.